Objective: This study aims to examine the clinical utility of the combination of TNM stage and modified Glasgow Prognostic Score (mGPS) in patients undergoing potentially curative resection of colorectal cancer (CRC). Background: Of measures of the systemic inflammatory response, the mGPS has been most extensively validated in patients with cancer. Methods: Data from 1000 consecutive patients undergoing potentially curative CRC resection from a single institution (January 1997-May 2013) were included. The relationship between mGPS [0-C-reactive protein (CRP) 10 mg/L, 1-CRP > 10 mg/L and albumin !35 g/L, 2-CRP > 10 mg/L and albumin < 35 g/L], TNM stage, and cancer-specific survival (CSS) and overall survival (OS) was examined using Kaplan-Meier log-rank survival analysis and multivariate Cox regression analysis. Results: An mGPS of 0, 1, and 2 was observed in 63%, 21%, and 16% of patients, respectively. Median follow-up was 56 months (interquartile range: 28-107 months). TNM and mGPS were independently associated with CSS and OS (all P < 0.001). In all patients, TNM and mGPS stratified 5-year CSS and OS from 97% and 87% (stage I, mGPS ¼ 0) to 32% and 26% (stage III, mGPS ¼ 2), respectively. In patients undergoing elective resection of colon cancer (n ¼ 575), 5-year CSS and OS ranged from 100% and 87% (stage I, mGPS ¼ 0) to 37% and 30% (stage III, mGPS ¼ 2), respectively. Conclusions: This study shows how the combination of TNM and mGPS effectively stratifies outcome in patients undergoing potentially curative resection of CRC. These data support routine staging of both the tumor and the host in patients with CRC.
C olorectal cancer is the third most common cancer in the Western World and the second most common cause of cancer death. 1 Currently, the need for adjuvant therapy is primarily based on pathological staging of the resected tumor using TNM criteria. 2 However, such a scheme may fail to accurately distinguish patients at high risk of recurrence and cancer death, particularly in the context of lymph node negative disease. 3 Characteristics pertaining to the host, such as emergency presentation, 4 are also independently associated with poorer oncological outcome. Furthermore, the presence of an elevated systemic inflammatory response, as evidenced by changes in circulating acute phase proteins or myeloid cells, is an important unifying host characteristic and has been consistently associated with reduced survival, independent of stage, across a number of cancers including colorectal cancer. 5, 6 Systemic inflammation-based prognostic scores, such as the modified Glasgow Prognostic Score (mGPS) and the neutrophil:lymphocyte ratio have been repeatedly reported to have prognostic value in a variety of operable cancers. 5, 6 Of these, the mGPS, a cumulative score based on the presence of an elevated serum C-reactive protein (CRP) and decreased serum albumin, has been reported to have superior prognostic value compared to the neutrophil:lymphocyte ratio in patients with operable colorectal cancer. [7] [8] [9] [10] Although the prognostic value of the mGPS has been widely reported, how it might be incorporated into the existing TNM-based staging of colorectal cancer, and how it might be implemented in the context of routine clinical practice and clinical trials is not clear. In this study, the clinical utility of assessment of the systemic inflammatory response, utilizing preoperative mGPS, was examined in a large cohort of patients undergoing potentially curative resection of colorectal cancer.
PATIENTS AND METHODS
Patients were identified from a prospectively collected and maintained database of elective and emergency colorectal cancer resections undertaken in a single surgical unit at Glasgow Royal Infirmary. Consecutive patients who had preoperative measurement of serum CRP and serum albumin within 30 days before surgery and those who on the basis of preoperative abdominal computed tomography and laparotomy findings were considered to have undergone potentially curative resection for colorectal adenocarcinoma without distant metastases between January 1997 and May 2013 were included. Patients with inflammatory bowel disease-related cancer, who underwent resection with palliative intent or local resection only, or had not had preoperative measurement of CRP or albumin, were excluded.
Tumors were staged using the fifth edition of the TNM classification, 2 with additional data taken from pathological reports issued after resection. After surgery, all patients were discussed at a colorectal multidisciplinary meeting involving surgeons, oncologists, radiologists, and pathologists with special interest in colorectal cancer; patients with stage III or high-risk stage II disease and no significant comorbidities precluding chemotherapy use were offered primarily 5-fluorouracil-based adjuvant chemotherapy on the basis of current guidelines at the time.
Preoperative serum CRP and albumin were recorded prospectively. Patients undergoing elective resection had serum CRP and albumin concentrations measured routinely within 30 days before elective surgery. In patients undergoing emergency resection, CRP and albumin measured on admission were recorded. The mGPS was constructed as previously described 5 (patients with a CRP 10 mg/L were allocated a score of 0, a CRP > 10 mg/L and albumin ! 35g/L a score of 1, and a CRP > 10mg/L and albumin < 35g/L a score of 2).
Patients were routinely followed up for 5 years after surgery. Date and cause of death was crosschecked with the cancer registration system and the Registrar General (Scotland). Death records were complete until March 31, 2014, that acted as the censor date. Cancer-specific survival (CSS) was measured from date of surgery until date of death from recurrent or metastatic colorectal cancer. Overall survival (OS) was measured until the date of death from any cause.
The relationship between clinicopathological characteristics, preoperative mGPS, and 5-and 10-year survival was examined using Kaplan-Meier log-rank survival analysis and univariate Cox proportional hazards regression to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs). Variables statistically significant on univariate analysis were subsequently entered into a multivariate model using a backwards conditional method. The relationship between mGPS and clinicopathological characteristics was examined using the x 2 method for linear trend. A P 0.05 was considered statistically significant. All analyses were performed using SPSS version 22.0 (IBM Corp, Armonk, NY). The West of Scotland Research Ethics Committee approved the study.
RESULTS
One thousand patients who underwent potentially curative resection of colorectal cancer were studied. Clinicopathological characteristics are shown in Table 1 . Data on neoadjuvant therapy, adjuvant therapy, and tumor differentiation were missing in 19, 2, and 10 patients, respectively. Two thirds of patients were older than 65 years at the time of surgery, 55% were male, and more than 90% of patients underwent elective resection. Two thirds of patients underwent resection of colon cancer. Ninety-three patients with rectal cancer and 5 patients with colon cancer received neoadjuvant therapy before surgery; of these, 13 patients with rectal cancer had pathological confirmation of stage 0 disease (complete pathological response). Overall, 15% of patients had stage I disease, 46% had stage II disease, and 38% had stage III disease. A quarter of patients received adjuvant chemotherapy after surgery; 16% of patients with stage II disease and 45% of patients with stage III disease received adjuvant therapy.
Thirty-seven percent of patients had CRP more than 10 mg/L, and 26% had an albumin less than 35 g/L before surgery. Almost two thirds of patients were mGPS ¼ 0, whereas 21% and 16% were mGPS ¼ 1 and mGPS ¼ 2, respectively. An elevated mGPS was associated with advancing age, emergency presentation (both 0.001), less frequent use of neoadjuvant therapy (P < 0.05), colonic primary, advancing T stage, advancing TNM stage, poor tumor differentiation, surgical margin involvement, peritoneal involvement, and tumor perforation (all P 0.001).
The median follow-up of survivors was 56 months (range: 10-206 months; interquartile range: 28-107 months), with 242 colorectal cancer-related deaths and 193 non-cancer-related deaths. CSS and OS at 5 and 10 years were 75% and 67% and 64% and 43%, respectively. The relationship between clinicopathological characteristics, preoperative mGPS, and survival is shown in Table 2 . The following clinicopathological characteristics were associated with reduced CSS on univariate analysis: mGPS (P < 0.001), advancing age (P < 0.01), emergency presentation (P < 0.01), T stage (P < 0.001), N stage (P < 0.001), poor differentiation (P < 0.01), venous invasion (P < 0.001), margin involvement (P < 0.001) and peritoneal involvement (P < 0.001). On multivariate survival analysis, mGPS was associated with reduced CSS (HR ¼ 1.28; P ¼ 0.003), independent of age (P < 0.01), T stage (P < 0.001), N stage (P < 0.001), and margin involvement (P < 0.001). Poor differentiation and venous invasion showed a trend toward reduced survival on multivariate analysis (P ¼ 0.086 and P ¼ 0.094, respectively), whereas emergency presentation, peritoneal involvement, and tumor perforation were not associated with survival.
The following clinicopathological characteristics were associated with reduced OS on univariate analysis: mGPS (P < 0.001), advancing age (P < 0.001), emergency presentation (P < 0.05), no adjuvant therapy (P < 0.05), T stage (P < 0.001), N stage (P < 0.001), poor differentiation (P ¼ 0.001), venous invasion (P < 0.01), margin involvement (P < 0.001), and peritoneal involvement (P < 0.001). On multivariate analysis, mGPS was associated with reduced OS (HR ¼ 1.28, P < 0.001), independent of age (P < 0.001), adjuvant therapy use (P < 0.05), T stage (P < 0.05), N stage (P < 0.001), differentiation (P < 0.05), and margin involvement (P < 0.001). Venous invasion showed a trend toward reduced OS (P ¼ 0.066), whereas emergency presentation, peritoneal involvement, and tumor perforation were not associated with survival.
The relationship between preoperative mGPS, TNM stage, and cancer-specific and OS is shown in Figure 1 and Tables 3 and 4 . CSS at 5 years varied from 100% in patients with stage 0 colorectal cancer to 61% in patients with stage III disease and from 80% in patients with mGPS ¼ 0 to 61% in patients with mGPS ¼ 2. When combined, CSS at 5 years varied from 100% in patients with stage 0 disease and mGPS ¼ 0, to 32% in patients with stage III disease and mGPS ¼ 2 (P < 0.001). A similar relationship between TNM stage, mGPS, and 10-year CSS was also observed; whereas survival ranged from 100% to 52% and from 70% to 52% with TNM stage or mGPS alone, the combination of TNM and mGPS stratified 10-year survival from 100% (TNM 0, mGPS ¼ 0) to 32% (TNM III, mGPS ¼ 2). The synergistic nature of the relationship between TNM stage and mGPS is, for example, shown for TNM stage III in Figure 2A (P < 0.001).
OS at 5 years varied from 92% (stage 0) to 51% (stage III) and from 70% (mGPS ¼ 0) to 46% (mGPS ¼ 2). Ten-year OS varied from 
The synergistic effect of the combination of TNM stage and mGPS on OS is again evident in Figure 2B (P < 0.001).
As mGPS was associated with emergency resection and a colonic primary, to control for any confounding of these variables the relationship between TNM stage, mGPS, and survival was examined for 575 patients undergoing elective resection of colon cancer. In patients undergoing elective resection of colon cancer, an elevated mGPS was associated with advancing age, advancing T stage and TNM stage, poor differentiation, surgical margin and peritoneal involvement, and tumor perforation ( Table 5 ). The median followup of survivors was 56 months (range: 10-206 months; interquartile range: 27-107 months), with 122 cancer-related deaths and 124 non-cancer-related deaths. CSS and OS were 79% and 66%, respectively, at 5 years and 70% and 43% at 10 years. On multivariate analysis, mGPS was associated with reduced CSS (HR ¼ 1.61, 95% CI: 1.28-2.02, P < 0.001), independent of age (P < 0.05), T stage (P ¼ 0.001), N stage (P < 0.001), and reduced OS (HR ¼ 1.52, 95% CI: 1.29-1.78, P < 0.001), independent of age (P < 0.001), no adjuvant therapy (P < 0.05), N stage (P < 0.001), and margin involvement (P ¼ 0.001) (Supplementary Table 1 , available at http://links.lww.com/SLA/A944). Venous invasion, peritoneal involvement, and tumor perforation were not associated with CSS or OS on multivariate analysis.
In patients undergoing elective resection of colon cancer, CSS at 5 years ranged from 96% in patients with stage I disease to 63% in patients with stage III disease and from 86% in patients with mGPS ¼ 0 to 64% in patients with mGPS ¼ 2 (both P 0.001) ( Figs. 3A, B ; Table 6 ). CSS at 10 years ranged from 96% (stage I) to 54% (stage III) and from 76% (mGPS ¼ 0) to 49% (mGPS ¼ 2). The combination of TNM stage and mGPS stratified both 5-and 10-year CSS from 100% (stage I, mGPS ¼ 0) to 37% (stage III, mGPS ¼ 2) (P < 0.001). OS ranged from 79% (stage I) to 54% (stage III) and from 75% (mGPS ¼ 0) to 46% (mGPS ¼ 2) at 5 years, and from 44% (stage I) to 38% (stage III) and 54% (mGPS ¼ 0) to 24% (mGPS ¼ 2) at 10 years (both P 0.001) (Figs. 3C, D; Table 7 ). The combination of TNM stage and mGPS stratified OS at 5 years from 87% (stage I, mGPS ¼ 0) to 30% (stage III, mGPS ¼ 2) and at 10 years from 53% (stage I, mGPS ¼ 0) to 17% (stage III, mGPS ¼ 2) (P < 0.001). Subgroup analysis was subsequently performed to examine the relationship between mGPS, use of adjuvant chemotherapy, and CSS of 205 patients undergoing elective resection of stage III colon cancer. Use of adjuvant chemotherapy was associated with younger age (P < 0.001), less advanced T stage, and a lower mGPS (both P < 0.05) but no other clinicopathological characteristics. The median follow-up of survivors was 61 months (range: 11-205 months; interquartile range: 31-107 months) with 71 cancer-related deaths. CSS was 79% at 5 years and 64% at 10 years for patients with stage III colon cancer who received adjuvant chemotherapy, compared to 51% and 47%, respectively, for patients who did not receive adjuvant therapy (P ¼ 0.002) ( Table 8 ). The mGPS stratified survival of patients with stage III colon cancer irrespective of adjuvant therapy status; for example, 5-year survival varied from 91% (mGPS ¼ 0) to 61% (mGPS ¼ 1) for patients who received adjuvant therapy (P ¼ 0.003), and varied from 60% (mGPS ¼ 0) to 34% (mGPS ¼ 2) for patients who did not receive adjuvant therapy (P ¼ 0.114). Furthermore, whereas use of adjuvant therapy was associated with increased survival in patients with mGPS ¼ 0 (P ¼ 0.003), it was not associated with improved survival in patients with an elevated mGPS (P ¼ 0.357).
Finally, subgroup analysis was performed to examine the relationship between mGPS, American Society of Clinical Oncology (ASCO) high-risk pathological criteria (presence of a T4 tumor, lymph node yield <10 nodes, poor tumor differentiation, tumor perforation, or venous invasion), and CSS of 239 patients undergoing elective resection of stage II colon cancer without subsequent adjuvant therapy. The median follow-up of survivors was 63 months (range: 10-205 months; interquartile range: 28-111 months), with 41 cancer-related deaths. Five-and 10-year survival of patients with no high-risk pathological characteristics was 91% and 85%, respectively, compared to 83% and 70% for patients with 1 or more high-risk characteristic (P ¼ 0.138) ( Table 9 ). An elevated mGPS was associated with reduced survival of patients with both low and high-risk stage II colon cancer; 10-year survival of patients with low-risk disease was stratified from 88% (mGPS ¼ 0) to 68% (mGPS ¼ 2) (P ¼ 0.035), and 10-year survival of patients with high-risk disease varied from 71% to 51% (P ¼ 0.042).
DISCUSSION
The results of this study show how the combination of TNM and mGPS effectively stratifies outcome in patients undergoing potentially curative resection of colorectal cancer. These data support the routine staging of both the tumor and the host systemic inflammatory response in patients with colorectal cancer.
In this study, an increasing mGPS was associated with the presence of high-risk clinicopathological characteristics pertaining to both the host and the tumor. Even so, the preoperative mGPS was prognostic independent of TNM stage and routinely reported adverse tumor characteristics, such as peritoneal involvement and tumor perforation. Furthermore, although associated with emergency presentation and a colonic primary, which may potentially reflect sitespecific tumor heterogeneity, 11 it was of interest that the mGPS retained independent prognostic utility in the context of elective resection of colon cancer. Indeed, the combination of TNM stage and mGPS increased the range of survival compared to either TNM or mGPS alone. For example, whereas 5-year CSS of all patients undergoing elective resection of stage III colon cancer was 63%, the addition of mGPS stratified survival from 75% to 37%. Furthermore, within stage II disease, it was possible to identify a fifth of patients undergoing resection at higher risk than that afforded by TNM criteria alone.
This study was able to provide further insight regarding the relationship between systemic inflammatory responses and use of adjuvant chemotherapy for stage III colon cancer. Patients with an elevated mGPS before elective resection were less likely to receive adjuvant therapy. At the time of data collection, however, it was unlikely to have been a factor in the multidisciplinary team's decision to recommend chemotherapy. Furthermore, although an elevated mGPS was associated with advancing age, more than 40% of patients who did not receive chemotherapy were younger than 75 years at the time of surgery. With such observational studies, there is a concern that one might be examining a population with an associated but unrelated (to cancer) chronic inflammatory state, which also was associated with a lower rate of adjuvant therapy. However, the common chronic inflammatory conditions, such as rheumatoid arthritis, do not normally preclude adjuvant chemotherapy. It is therefore of interest that an elevated mGPS has previously been associated with comorbid status 12, 13 and the presence of postoperative infectious complications. 14 However, although both may preclude use of adjuvant chemotherapy and explain the present inverse association between mGPS and use of adjuvant therapy, 15 it is important to note that the relationship between mGPS and oncological outcome has previously been shown to be independent of underlying patient comorbidity. 13, 16 Of interest, the mGPS stratified the survival of patients who received adjuvant chemotherapy after resection of stage III colon cancer. Although the present analysis must be interpreted with caution, it is consistent with previous reports. 5 Indeed, in this study, although patients with mGPS ¼ 0 had a 50% relative increase in survival at 5 years with adjuvant therapy, patients with mGPS more than or equal to 1 appeared to derive no benefit. The underlying mechanism responsible for this lack of benefit is unclear; whereas it may be indicative of reduced tolerance to chemotherapy leading to subsequent dose reduction or cessation of treatment, 17 it may simply represent a lack of efficacy in the systemically inflamed patient. Certainly, although secondary analyses of reported trials of adjuvant chemotherapy may provide further insight, it is clear that future studies of adjuvant therapies should incorporate assessment of the preoperative systemic inflammatory response. Although there is clear rationale for the use of adjuvant chemotherapy in patients with stage III colon cancer, the postoperative management of lymph node-negative disease is problematic. 3 Other high-risk pathological characteristics, such as the presence of venous invasion, have been shown to effectively stratify outcome within TNM and may predict need for adjuvant therapy. 18 However, the recent inclusion of venous invasion alongside other high-risk pathological characteristics as additional prognostic factors in tumor staging does not negate the utility of host characteristics, such as the mGPS, in the effective stratification of outcome. Indeed, in this study, patients with mGPS ¼ 2 undergoing elective resection for otherwise low-risk stage II colon cancer had 5-and 10-year survival comparable to that of patients with stage III disease. Although the small number of patients receiving adjuvant therapy for stage II colon cancer precluded meaningful analysis in this study, whether the mGPS may aid in the selection of patients with stage II colon cancer likely to benefit from adjuvant therapy would be of considerable interest. Furthermore, whereas assessment of pathological characteristics are often subjective and may be underreported, 19 the components of the mGPS, CRP and albumin, are objectively measured and routinely available. This study was limited by its single-center nature; however, this was a large, prospectively collected cohort of patients. Although a population whose mGPS reverted to normal after surgery would be of interest, the majority of patients do not appear, in terms of their mGPS, to change their inflammatory state. Indeed, of those patients with an elevated mGPS, up to 80% may remain systemically inflamed after potentially curative resection of colorectal cancer. 9 As such, any changes to the operative and perioperative management of patients over the time period studied, for example, the introduction of enhanced recovery protocols to our center in 2011, are unlikely to have had a significant effect on an elevated mGPS. Furthermore, the small number of patients undergoing resection for stage I colon cancer and patients with rectal cancer precluded meaningful analysis within these subsets. Given that earlier-stage disease is likely to predominate in the context of colorectal cancer screening program, 20 whether mGPS may aid in the decision between local excision and formal resection in patients presenting with early-stage disease would be an important area for future research. Finally, as mGPS was only recorded before surgery, it was not possible to examine the impact of neoadjuvant chemoradiotherapy on the mGPS of patients with rectal cancer. This would also be of considerable interest.
Although representing only ''the tip of a far larger iceberg'' in inflammation-associated tumor progression and dissemination, 21 the use of routinely available biomarkers, such as the mGPS, allows us to utilize our current understanding of the systemic inflammatory responses in patients with cancer. This has several far-reaching implications for clinical practice. As demonstrated, alongside guiding long-term prognosis, the incorporation of the mGPS into routine assessment may also identify patients less likely to tolerate, or benefit from, adjuvant systemic therapy. Furthermore, routine use of the mGPS may also direct future therapeutic strategies, targeted at the systemic inflammatory response itself. Indeed, it is now appreciated that systemic inflammation is complicit in cancer cachexia 22 and may be attenuated by the use of nonsteroidal anti-inflammatory drugs. 23 A similar scheme may also be applied to patients undergoing potentially curative surgery. For example, in patients with stage III disease, those with mGPS ¼ 0 may benefit from adjuvant chemotherapy alone, whereas those with an elevated mGPS may also benefit from the addition of an anti-inflammatory agent, such as aspirin or other nonsteroidal anti-inflammatory drug. 24, 25 Certainly, it is clear that randomized controlled trials, incorporating both routine assessment of the systemic inflammatory response and use of anti-inflammatory agents, are required.
CONCLUSIONS
The mGPS provides complimentary prognostic information to current TNM-based staging and may also aid in directing future therapeutic strategies, targeting the systemic inflammatory response. Given that the combination of TNM stage and the mGPS are routinely available worldwide, this staging system for patients undergoing potentially curative resection of colorectal cancer has much to commend it. Values are expressed as % (standard error).
Ã
High-risk stage II colon cancer denoted by presence of 1 or more of the following: T4 tumor, lymph node yield < 10 nodes, poor tumor differentiation, tumor perforation, or venous invasion.
